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Abstract
Telomeres have been postulated as a universal clock that shortens in parallel with cellular aging. They are
specialized DNA–protein structures at the ends of chromosome with remarkable functions—preventing their
recognition as double-stranded DNA breaks, protecting their recombination and degradation, and avoiding a
DNA damage cellular response. Telomere shortening is currently considered the best aging marker, but is also a
predictor for age-related diseases, including cardiovascular diseases. Biological age clearly seems to be a better
predictor of vascular risk rather than chronological age. This concept is supported by key assumptions that
peripheral blood leukocyte telomere content accurately reflects that of the vascular wall and its decrease is
associated with premature vascular disease. Thus, we are analyzing whether the mean of blood leukocyte
telomere length might also be a predictor for sporadic thoracic aortic aneurysm (S-TAA). The preliminary results
seem to be promising. Shorter telomeres were detected in patients than in controls. Thus, mean of blood
leukocyte telomere length could contribute to identify individuals at S-TAA risk.
Introduction
The prevalence of cardiovascular diseases (CVD)rises with aging and is one of the main causes of mor-
tality in Western countries. In view of the progressive pop-
ulation aging, a better understanding of age-associated
diseases, including CVD, and preventive measures are nee-
ded. Among CVD, sporadic thoracic aortic aneurysm (S-
TAA), the major disease affecting the aorta, has increased
incidence particularly in the aged population, as reported by
reliable epidemiological observations.1–4
S-TAA is predominantly a silent illness, until rupture or
dissection occurs, and is insidious in its onset and progres-
sion.1–3 It has a complex pathophysiology that differs from
that of abdominal aorta aneurysm (AAA) principally associ-
ated with atherosclerosis.1–3 Several cardiovascular risk factors
(i.e., hypertension, oxidative stress, smoking, etc.) seem to
explain most risk of S-TAA in the general population.1–3
However, little is known about its precise cellular and mo-
lecular mechanisms and genetic determinants.1–3 In particular,
at an individual level, there is wide variation in both its oc-
currence and complications (i.e., dissection and rupture) and
age and gender manifestation, even in individuals with the
same risk factor profiles.1–3 The reasons for this wide interin-
dividual variation in susceptibility are poorly understood.
However, it is currently emerging that interindividual varia-
tion in CVD risk, such as S-TAA, is a result of variability in the
rate of biological aging.5,6
Recent studies suggest that biological age rather than
chronological age is a better predictor of vascular risk.6–11
This assumption is based on the evidence that telomere
content (the TTAGGG DNA repeats at the ends of chromo-
somes) in circulating blood leukocytes accurately reflects the
biological age of the vascular wall, as recently demonstrated
by Wilson et al.12 Furthermore, a series of recent epidemio-
logical studies have demonstrated association of the reduc-
tion of blood telomere length with several CVD, such as
AAA.6–12 Patients with AAA showed a shorter leukocyte
telomere length compared to controls, as verified by Atturu
et al.13 In light of this evidence, our studies are aimed at
determining whether the mean of blood leukocyte telomere
length might be a predictor for S-TAA.
Materials and Methods
Peripheral blood samples were collected from 161 S-TAA
patients and 128 age- and gender-matched controls (61 [47%]
men and 67 [53%] women; mean age, 61.08– 5.83 years]. The
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clinical and demographic features of patients are summa-
rized in Table 1. For patient selection, the 2010 guidelines,14
histopathological and phenotypic analyses, and exclusion
criteria for syndromic and familial forms (e.g., Marfan and
Ehler–Danlos syndromes) and autoimmune connective tis-
sue disorders were used. The controls were in good health
according to their clinical history and blood tests (complete
blood cell count, erythrocyte sedimentation rate, glucose,
urea nitrogen, creatinine, electrolytes, C-reactive protein,
liver function tests, iron, and proteins). Concerning the major
cardiac risk factors, smoking (51%), hypertension (31%),
cardiovascular ischemic familiarity (27%), dyslipidemia
(16%), and diabetes mellitus (13%) were evidenced (see Table
1). Furthermore, ECHO imaging examinations confirmed
absence of any aorta wall abnormalities in all controls. We
selected a very homogeneous population; patients and con-
trols belonged to same ethnic group (their parents and
grandparents were born in western Sicily).
Our study received approval from local ethic committees,
and all participants gave their informed consent. Data were
encoded to ensure patient and control protection. All mea-
surements were performed without knowledge about nature
of material.
Genomic DNA was extracted from leukocytes of both the
two cohorts and the mean terminal restriction fragment
(TRF) length, a marker of telomere length, was measured by
a chemiluminesence technique using TeloTAGGG Telomere
Length Assay kits (Roche-Applied Science, Germany). In the
present pilot study, we examined the mean TRF length in 10
patients and 10 controls selected randomly, but having the
Table 1. Demographic and Clinical Characteristics of 161 S-TAA Patients and 128 Controls
Variables Patients Male Female Controls
P1 (cases vs.
controls)
P2 (male vs.
female)
Demographic characteristics n = 161 n= 127 n = 34 n= 128
Age, mean (standard deviation, SD) 63 (10.7) 63 (11) 64 (9) 61.1(5,8) 0.834 0.594
Male sex, number (%) 127 (78) 61 (47)
Female sex, number (%) 34 (22) 67 (53)
Body mass index, mean (SD) 27 (4.3) 26.9 (3.8) 27.5 (5.6) 26.9(2.9) 0.898 0.963
Size and location
Size (mm), mean (SD) 53.3 (8) 52.9 (7.5) 55 (9.8) 0 (0) 0.191
Location, number (%): 0 (0) 0.198
Ascending aorta 81 (50) 20 (59) 61 (48)
Aortic bulb 18 (11) 1 (3) 17 (13.4)
Ascending aorta and aortic bulb 62 (39) 13 (38) 49 (38.6)
Co-morbidity conditions, number (%)
Aortic aneurysm familiarity 9 (5.5) 8 (6.2) 1 (0.3) 0 (0) 0.026 0.736
Cardiovascular Ischemic familiarity 59 (36.6) 48 (38) 11 (32) 34 (27) 0.089 0.7
Smoking 73 (45) 67 (53) 6 (18) 66 (51) 0.351 < 0.001
Hypertension 127 (78.9) 101 (80) 26 (76) 40 (31) < 0.001 0.879
Dislipidemy 37 (23) 30 (24) 7 (21) 20 (16) 0.158 0.886
Diabetes mellitus 24 (15) 16 (13) 8 (24) 16 (13) 0.677 0.187
Renal failure 5 (3.1) 4 (3.1) 1 (2.9) 0 (0) 0.168 0.621
Dissection 18 (11) 5 (15) 13 (10) 0 (0) 0.669
Bicuspid aortic valve disease 27 (16.8) 21 (16.5) 6 (18) 0 (0) 0.92
Aortic valve pathology, number (%) 0.766
Normal 90 (56) 71 (56) 20 (59) 0 (0)
Prolapse 21 (13) 17 (13) 3 (9) 0 (0)
Vascular calcium fibrosis 50 (31) 39 (31) 11 (32) 0 (0)
Aortic valve dysfunction, number (%) 0.91
Normal 32 (20) 26 (20.4) 6 (17.6) 0 (0)
Faint incontinence 29 (18) 22 (17) 7 (20.4) 0 (0)
Moderate incontinence 34 (21) 28 (22) 6 (17.6) 0 (0)
Severe incontinence 44 (28)) 35 (28) 9 (26.4) 0 (0)
Faint stenosis 1 (0.6) 1 (0.8) 0 (0) 0 (0)
Moderate stenosis 2 (1.2) 1 (0.8) 1 (3) 0 (0)
Severe stenosis 19 (11.2) 14 (11) 5 (15) 0 (0)
Atherosclerosis coronary syndrome, number (%) 54 (33.8) 45 (36) 9 (26.5) 0 (0) 0.42
Drugs, number (%)
Beta blockers 62 (39) 47 (37) 15 (44) 0 (0)
Central a-adrenergic agonists 26 (16) 21 (17) 5 (15) 0 (0)
Sartans 32 (20) 27 (21) 5 (15) 0 (0)
Calcium-channel blockers 47 (29) 38 (30) 9 (26) 0 (0)
Angiotensin-converting enzyme (ACE) inhibitors 66 (41) 55 (43) 11 (32) 21 (16)
Antidiabetic drugs 19 (12) 13 (10) 6 (18) 16 (13)
Antiaggregant drugs 51 (32) 44 (34) 7 (21) 40 (31)
Antidyslipidemic drugs 36 (22) 30 (24) 6 (18) 0 (0)
Diuretics 36 (22) 24 (19) 12 (36) 40 (31)
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same age and gender. Accordingly, the same number of males
and females characterized both the two cohorts studied.
Statistical analysis
The difference in mean TRF length between cases and
controls was analyzed using an independent sample t-test.
The difference in mean TRF length in subjects with different
risk factors was analyzed using bivariate correlation for
continuous variables and an independent samples t-test for
categorical variable. The independent effect of age, sex, and
other risk factors on the mean TRF length was analyzed
using a linear regression model controlling for case–control
status.
Results
All patient and control features of our cases are summa-
rized in Table 1. An elevated number of S-TAA men (127 vs.
34 women) led to comparison of all patient features ac-
cording to gender. Comparisons were also detected between
cases and controls (see Table 1).
In the present pilot study, we examined only 10 patients
and 10 controls selected randomly, but considering the same
age and gender. The evaluation of the mean TRF length in
the two groups and their analysis demonstrated that the
mean TRF length of S-TAA group (5.550, standard deviation
[SD] = 0.605 kbp) was significantly lower than that observed
in the control group (6.739, SD = 0.485 kbp) (Fig. 1). A dif-
ference of 1.189 bp was observed between cases and controls
(95% confidence interval [CI] 77–301 bp, p = 0.001). There was
no significant change in the mean TRF length with age in
both patients and controls (6 bp increase per year, SD= 4;
p = 0.16). There was also no significant correlation between
aneurysm size and mean TRF length ( p= 0.35). There was no
significant difference in the mean TRF length between male
and female patients. The difference in mean TRF length be-
tween subjects based on risk factors such as gender, smok-
ing, hypertension, diabetes, and family history of S-TAA was
evaluated. Sex as an independent risk factor did not have
any significant effect on the mean TRF length ( p = 0.99). In
contrast, smoking and hypertension in S-TAA cases were the
only risk factors that were significantly associated with the
mean TRF length ( p= 0.03). S-TAA subjects with smoking
and hypertension histories had a significantly shorter mean
TRF length (5.491, SD = 0.485) compared to subjects without
these risk factors (5.684, SD = 0.502) (mean difference 192 bp,
CI 7–378 bp, p= 0.02).
Discussion
A remarkable variability exists in the susceptibility, onset
age, and steps of progression for CVD, including S-TAA, and
this has been inadequately explained by the presence or
absence of conventional risk factors. Today, it has been as-
sumed that differences in biological aging might provide an
additional and more appropriate component of the observed
variability.5,6 In particular, telomere length provides a po-
tential marker of an individual’s biological age, and shorter
telomeres reflect a more advanced biological age. 5,6 Telo-
mere length at birth is determined mainly by genetic factors.5
Telomere attrition occurs as a consequence of cellular repli-
cation and can be accelerated by dangerous environmental
factors, such as oxidative stress and smoking, as well and
is largely documented.6 When telomeres reach a critical
threshold, the cell will enter senescence and become dys-
functional.5,6 Furthermore, within an individual, there is a
high similarity in telomere length between various tissues.5,6
As consequence, leukocyte telomere length is commonly
used as an optimal marker for overall telomere length. In
particular, peripheral blood leukocyte telomere content ac-
curately reflects that of vascular wall, and its decrease is
associated with premature vascular disease.12 So, the blood
leukocyte telomere DNA content may be used as a conve-
nient surrogate for vascular aging in population studies.12
On the basis of these observations, not unexpectedly
a series of epidemiological studies have demonstrated an as-
sociation between blood telomere length and aging-related
diseases, such as CVD. Shorter telomeres have been demon-
strated in subjects with several CVD pathologies, including
chronic heart failure, atherosclerosis, ventricular dysfunction,
coronary artery calcification, and aortic valve stenosis.6–12
Furthermore, telomere length has been also identified as an
independent predictor of heart disease–related events. 6–12 In
addition, a significant reduction in telomere content of AAA
wall samples compared to normal aorta and in AAA patients
than controls has been detected.12,13
The mechanisms linking blood telomere attrition to CVD
have been studied recently,6 and number of potential ex-
planations have been suggested.6 First, the strong association
between human blood leukocyte and vessel wall telomere
content may be determined genetically, and shorter telo-
meres may predispose to CVD development.6 In contrast, it
has been assumed that the shorter telomeres in individuals
with CVD may be acquired due to accelerated telomere at-
trition in the blood leukocyte and vessel wall occurring in
tandem following exposure to CVD risk factors, such as
hypertension, diabetes, dyslipidemia, obesity, and smoking.6
Chronic inflammation and oxidative damage to DNA are
probable common mechanisms for the latter hypothesis.6 On
the other hand, we have particularly outlined in our studies
the key role of inflammation in CVD pathophysiology.15,16
Accordingly, it is plausible that the actual length of the
FIG. 1. The mean terminal restriction fragment (TFR)
length in the two cohorts. (White bar) Sporadic thoracic
aortic aneurysm (S-TAA) cases; (black bar) controls.
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telomere in the vessel wall has less to do with the process of
aging and is simply the result of an inflammatory process
that shortens telomeres in parallel in many tissues.6
In the light of these observations, we examined whether the
mean of blood leukocyte telomere length might be a predictor
for S-TAA. The preliminary results obtained are promising
and show that S-TAA patients have significantly shorter leu-
kocyte TRF length compared to controls. Furthermore, the
assessment of biological effects of S-TAA risk factors on leu-
kocyte TRF length showed that smoking and hypertension
were the only risk factors significantly associated with re-
duction of the mean TRF length ( p= 0.03). Their association
with a reduction of mean TRF length seems plausible with the
biological effects that they mediate on the aortic wall.6
Thus, our results, although based on a limited number of
cases and controls, seem to suggest that the mean of blood
leukocyte telomere length might be a predictor for S-TAA.
However, larger studies are needed to confirm and validate
our preliminary data. On the other hand, S-TAA is a well-
defined phenotype, and, consequently, we did not find diffi-
culty in identifying patients with this aorta wall disease.
Furthermore, we have measured blood telomere length using
terminal restriction fragment assay (Southern blot technique)
rather than the more recently developed assays like poly-
merase chain reaction or quantitative hybridization. Although
the terminal restriction fragment assay is time consuming and
laborious, it measures the telomere length directly rather than
measuring the telomere content. Thus, these experimental
conditions might assure obtaining very interesting data.
In conclusion, telomere assay could contribute to identify
individuals at risk for S-TAA. In addition, our results seem to
suggest that vascular biological aging might have a strong
role in the S-TAA pathogenesis. If it can be proved that
telomeres are not only associated but also causally involved
in the pathogenesis of S-TAA, this result might provide ex-
citing new avenues for the development of future preventive
and therapeutic strategies.
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